InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,246.68
(
0.48%
)
US TECH 100
17,845.20
(
0.69%
)
Dow Jones
39,558.11
(
0.32%
)
Brent Oil
82.76
(
0.25%
)
Bitcoin
61,868.45
(
0.52%
)
Post# of 251821
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119634
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rfj1862 post# 224180

Tuesday, 03/19/2019 12:10:15 PM

Tuesday, March 19, 2019 12:10:15 PM

Post# of 251821
ENTA is a sleeper entrant in the HBV arena. ENTA’s proven drug-discovery expertise in viral/liver diseases gives me confidence that their HBV core inhibitor will be a good one.

Among the new MoAs being tested by the various players are:

• Core-protein inhibition
• Capsid inhibition
• S-antigen inhibition
• RNA degradation

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up